DISCOVER OUR PIONEERING CONTRIBUTIONS TO ONCOLOGY THROUGH PRESTIGIOUS JOURNALS AND PLATFORMS LIKE ASCO, ESMO, AND SABCS. ELEVATE YOUR INSIGHTS WITH OUR CUTTING-EDGE CLINICAL TRIAL PUBLICATIONS.
EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT
PUBLICATIONS
THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.
STUDY
OFFICIAL TITLE
DISEASE
JOURNAL/
CONGRESS
YEAR
DOWNLOAD
OTHER
I-SPY2 platform: New lessons from the olaparib and durvalumab combination in breast cancer treatment
BREAST
(Journal) Cancer Cell
2021
LINGAIN
Analysis of αβ and γδ circulating T cells in the PHERGain randomized phase 2 trial for patients with HER2-positive early breast cancer receiving neoadjuvant trastuzumab and pertuzumab without chemotherapy: LINGain
BREAST
SABCS
2021
ABIGAIL
Phase 2 study of abemaciclib in combination with endocrine therapy with or without paclitaxel induction in patients with hormone receptor-positive, HER2-negative advanced breast cancer and aggressive disease criteria: ABIGAIL
BREAST
SABCS
2021
COPERNICO
Tocilizumab (T) plus pembrolizumab (P) in patients (pts) with Covid-19 pneumonia: COPERNICO
COVID-19
(Journal) ERS International Congress
2021
DXCARTES
Neoadjuvant letrozole plus palbociclib in patients with hormone receptor positive/HER2-negative breast cancer with baseline Ki67>20% and an Oncotype DX recurrence score* result >18: DXCARTES
BREAST
SABCS
2021
OTHER
Immune analysis of lymph nodes in relation to thepresence or absence of tumor infiltrating lymphocytes intriple-negative breast cancer
BREAST
(Journal) European Journal of Cancer
2021
PHERGAIN2
A phase 2 study of chemotherapy de-escalation using a pathological response-guided strategy in patients with HER2-positive, low-risk early breast cancer: PHERGain-2
BREAST
SABCS
2021
OTHER
Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects
BREAST
(Journal) Therapeutic Advances in Medical Oncology
2021
KELLY
Pembrolizumab plus eribulin in hormone-receptore positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label,multicentre, single-arm, phase II trial
BREAST
(Journal) European Journal of Cancer
2021
DEBBRAH
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive or HER2-low-expressing advanced breast cancer and central nervous system involvement: Preliminary results from the DEBBRAH phase 2 study
BREAST
SABCS
2021
PARSIFAL
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor–Positive,ERBB2-Negative Advanced Breast Cancer A Randomized Clinical Trial
BREAST
(Journal) JAMA Oncology
2021
AZENT
First-line osimertinib in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met
LUNG
(Journal) European Journal of Cancer
2021
Other MEDSIR related articles
